Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation TCT 2024

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

Presenter: David Kandzari

October 28, 2024

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

Caitlin E. Cox

October 27, 2023

Presentation TCT 2023

TCT 185: Safety and Performance Registry for an All-Comers Subject Population with the Limus Eluting Orsiro Mission Stent System Within Daily Clinical Practice: Twelve-Month Results of the BIOFLOW-VIII Registry

Presenter: Georg Nollert

October 25, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

Presentation TCT 2018

BIOFLOW V: Two-Year Results of a Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Fernando Alfonso, Juan F. Granada, David E. Kandzari

September 23, 2018

News Conference News TCT 2018

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

Michael O'Riordan

September 22, 2018

Presentation TCT 2018

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Presenter: Alexandre Abizaid, Didier Carrié, Ariel Roguin

September 21, 2018

News Conference News SCAI 2018

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

Shelley Wood

May 04, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Industry News

Biotronik launches China arm in Orsiro stent trial

August 31, 2015

Advertisement

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

TCT 185: Safety and Performance Registry for an All-Comers Subject Population with the Limus Eluting Orsiro Mission Stent System Within Daily Clinical Practice: Twelve-Month Results of the BIOFLOW-VIII Registry

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

BIOFLOW V: Two-Year Results of a Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent

Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Interventional Appetite Erodes for Dissolving Polymers and Scaffolds

TCTMD’s Top 10 Most Popular Stories for September 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Biotronik launches China arm in Orsiro stent trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content